Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


New EMA guideline for development of vaccines

The European Medicines Agency (EMA) has produced a new draft guideline for the clinical development of vaccines.

The guidelines, which have been put out for a six-month public consultation, include specific considerations for clinical trials of vaccines in special populations, such as pregnant women or older people.

The revised version of the guidelines also adds considerations to priming and boosting strategies. These include the option of heterologous prime-boost, which involves the administration of one type of vaccine followed by a different type of vaccine for the same pathogen later.

The guideline also addresses the need to develop vaccines for pathogens that may cause future epidemics, and for which conducting clinical trials outside of outbreaks might be problematic.

According to the World Health Organization, immunisation saves an estimated 2–3 million lives each year and protects against many dangerous diseases, including cervical cancer, diphtheria, hepatitis B, measles, mumps, pertussis (whooping cough), and tetanus.

Vaccines can also help limit the spread of antibiotic resistance, as vaccination is an effective way to stop people and animals getting infected, thereby preventing the need for antibiotics.

The EMA said once the revised guideline is adopted by the Committee for Medicinal Products for Human Use, the current guidelines on clinical evaluation of new vaccines will no longer apply.



Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2018.20204777

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Flu vaccine stocks

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.